Close

Jefferies Downgrades PTC Therapeutics (PTCT) to Underperform Amid Negative DMD AdCom

November 25, 2015 7:29 AM EST Send to a Friend
Jefferies downgraded PTC Therapeutics (NASDAQ: PTCT) from Hold to Underperform with a price target of $18.00 (from $26.00) following BioMarin's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login